These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38463163)

  • 1. Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants.
    Macías-Parra M; Vidal-Vázquez P; Reyna-Figueroa J; Rodríguez-Weber MÁ; Moreno-Macías H; Hernández-Benavides I; Fortes-Gutiérrez S; Richardson VL; Vázquez-Cárdenas P
    Front Public Health; 2024; 12():1356932. PubMed ID: 38463163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
    Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
    Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Maclehose H; Bergman H; Ben-Aharon I; Nagpal S; Goldberg E; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD008521. PubMed ID: 23152260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008521. PubMed ID: 30912133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Maclehose H; Bergman H; Ben-Aharon I; Nagpal S; Goldberg E; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008521. PubMed ID: 22336845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean.
    Velázquez RF; Linhares AC; Muñoz S; Seron P; Lorca P; DeAntonio R; Ortega-Barria E
    BMC Pediatr; 2017 Jan; 17(1):14. PubMed ID: 28086819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial.
    Kanungo S; Chatterjee P; Bavdekar A; Murhekar M; Babji S; Garg R; Samanta S; Nandy RK; Kawade A; Boopathi K; Kanagasabai K; Kamal VK; Kumar VS; Gupta N; Dutta S
    Lancet Infect Dis; 2022 Aug; 22(8):1191-1199. PubMed ID: 35588754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of pentavalent rotavirus vaccine in Chinese infants.
    Mo Z; Ma X; Luo P; Mo Y; Kaplan SS; Shou Q; Zheng M; Hille DA; Arnold BA; ; Liao X
    Vaccine; 2019 Mar; 37(13):1836-1843. PubMed ID: 30808567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.
    Levin MJ; Lindsey JC; Kaplan SS; Schimana W; Lawrence J; McNeal MM; Bwakura-Dangarembizi M; Ogwu A; Mpabalwani EM; Sato P; Siberry G; Nelson M; Hille D; Weinberg GA; Weinberg A
    AIDS; 2017 Jan; 31(1):49-59. PubMed ID: 27662551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants.
    Ella R; Babji S; Ciarlet M; Blackwelder WC; Vadrevu KM
    Vaccine; 2019 Jul; 37(31):4407-4413. PubMed ID: 31178377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.
    Mo Z; Mo Y; Li M; Tao J; Yang X; Kong J; Wei D; Fu B; Liao X; Chu J; Qiu Y; Hille DA; Nelson M; Kaplan SS
    Vaccine; 2017 Oct; 35(43):5897-5904. PubMed ID: 28935470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
    Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
    Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.
    Lawrence J; He S; Martin J; Schödel F; Ciarlet M; Murray AV
    Hum Vaccin Immunother; 2014; 10(8):2247-54. PubMed ID: 25424929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants.
    Cohet C; Cheuvart B; Moerman L; Bi D; Caplanusi A; Kariyappa M; Lalwani S; Mitra M; Sapru A; Saha S; Varughese PV; Kompithra RZ; Gandhi S
    Hum Vaccin Immunother; 2021 Nov; 17(11):4646-4653. PubMed ID: 34428112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
    Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
    Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Rotavirus Vaccination With Inpatient and Emergency Department Visits Among Children Seeking Care for Acute Gastroenteritis, 2010-2016.
    Payne DC; Englund JA; Weinberg GA; Halasa NB; Boom JA; Staat MA; Selvarangan R; Azimi PH; Klein EJ; Szilagyi PG; Chappell J; Sahni LC; McNeal M; Harrison CJ; Moffatt ME; Johnston SH; Mijatovic-Rustempasic S; Esona MD; Tate JE; Curns AT; Wikswo ME; Sulemana I; Bowen MD; Parashar UD
    JAMA Netw Open; 2019 Sep; 2(9):e1912242. PubMed ID: 31560386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States.
    Krishnarajah G; Davis EJ; Fan Y; Standaert BA; Buikema AR
    Vaccine; 2012 May; 30(24):3717-22. PubMed ID: 22214886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of different dosing schedules of the human live attenuate rotavirus vaccine (RV1) in infants and children: a meta-analysis.
    Dai X; Bai R; Jian M; Ji Z; Ding Z; Wang F; Bi Y; Manzamaesso A; Chen T; Luo L; Liu A; Bao F
    Hum Vaccin Immunother; 2019; 15(6):1228-1236. PubMed ID: 30346870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.